Names
Inrebic® FedratinibIndications and usage
Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Side effects needing medical attention
Diarrhea, nausea, anemia, and vomiting.